FDARA Would Trim $72 Million From Deficit Over 10 Years, CBO Says
Executive Summary
CBO score of the FDA use fee reauthorization bill only looks at changes in revenues and direct spending on a few provisions, and does not factor in changes in discretionary spending.
You may also be interested in...
Pediatric Cancer Study Requirements Added To FDA User Fee Bill
User fee legislation headed for a US House vote this week would require pediatric studies of certain molecularly targeted cancer drugs; the requirement, which could apply to some orphan drugs, would not take effect for three years.
Generic Program Is Biggest Extra Item In Senate User Fee Reauthorization Bill
US FDA would need additional appropriations to cover all activities contemplated in the legislation – and the bill appears to need a pay-for because it increases the deficit.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.